ClinicalTrials.gg
RecruitingNCT07084662Updated Nov 26, 2025

Xinlikang Capsule for Chemotherapy-induced Fatigue and Immune Disorders in Diffuse Large B Lymphoma

A Phase 2/3 interventional study of Xinlikang capsules and mimic capsules in Diffuse Large B-Cell Lymphoma (DLBCL), sponsored by Sun Yat-sen University. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-26.

Sponsored by Sun Yat-sen University · Phase 2/3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Lymphoma, Large B-Cell, Diffuse by Sun Yat-sen University — 10 open to participants now, 10 under way, 1 of them phase 3. Lymphoma, Large B-Cell, Diffuse · Sun Yat-sen University.

Planned enrollment
3rd of 13
80 · median 48
Started
2025
with 2 others
Phase 2/3
Only one
of the 17
Registered
13th of 17
by date

Among the 17 studies in Lymphoma, Large B-Cell, Diffuse by Sun Yat-sen University, this one is the 3rd largest by planned enrollment of the 13 interventional ones that give a count, is one of 3 that started in 2025, is the only one in phase 2/3, and was the 13th registered.

Lymphoma, Large B-Cell, Diffuse

1,873 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Open to participants now

10 of the 17 studies in Lymphoma, Large B-Cell, Diffuse by Sun Yat-sen University are open now, in 1 country. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Where they have run

Who these studies take

Of the 265 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 176 (66%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Lymphoma, Large B-Cell, Diffuse by Sun Yat-sen University, or all of them as a file.
02

Study summary

To evaluate the efficacy and safety of Xinlikang capsule in the treatment of cancer-related fatigue (CRF) and peripheral blood lymphocytes in patients with diffuse large B-cell lymphoma (DLBCL) who achieved complete remission (CR) after all courses of chemotherapy-containing regimens

03

Conditions studied

  • Diffuse Large B-Cell Lymphoma (DLBCL)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥18 years old;
  2. Newly diagnosed diffuse large B lymphoma (DLBCL);
  3. Patients had completed the treatment of chemotherapy and immunotherapy and the course of treatment had been completed.
  4. Metabolic complete response (CR) was evaluated by PET/CT during or after chemotherapy.
  5. Had completed the full course of chemotherapy-containing regimen for more than 30-90 days;
  6. BFI fatigue score ≥4;
  7. The expected survival time was ≥6 months;
  8. No treatment plan for CD20 monoclonal antibody, radiotherapy, chemotherapy, lenalidomide, thymopeptides, targeted drugs, biological agents, agents, other Chinese medicine decoction or Chinese patent medicine in the next 3 months;
  9. No grade 3-4 surgery plan is expected in the next 3 months;
  10. They had normal mental consciousness, could understand the content of the questionnaire correctly, and could complete the questionnaire with assistance or independently;
  11. Women and men of childbearing age agreed to use during and for 1 month after treatment;
  12. They volunteered to participate in the clinical trial and signed the form, which was in accordance with the requirements of Good Clinical Practice (GCP).

Exclusion criteria

Exclusion Criteria:

  1. DLBCL subjects with CNS involvement at initial diagnosis;
  2. Allergic or intolerant to Xinlikang capsule or its component drugs;
  3. Significant abnormal liver and kidney function: , AST, GGT≥3 ; BUN and Cr≥3 ULN;
  4. Severe abnormal bone marrow function: white blood cell ≤1.0×10\^9/L, neutrophil ≤0.5×10\^9/L, ≤30×10\^9/L, ≤6g/dL;
  5. Patients with virus infection, bacterial infection and other immune-related diseases that affect immune function as judged by clinicians;
  6. Uncontrolled or infection: Hepatitis B Virus (HBV) DNA testing exceeding the lower limit of detection or 1000 copies /mL or 500 IU/mL (the higher is the reference) during screening in patients with a history of chronic hepatitis B; HCV RNA detection in patients with a history of Hepatitis C Virus (HCV) infection during the screening period exceeded the detection limit of the assay or 1000 copies /mL or 500 IU/mL (whichever was higher was used as a reference).
  7. Patients with other .
  8. Enrollment in another clinical trial 30 days before screening or during the trial;
  9. Persons who were deemed by the investigator to be ineligible to participate in the trial.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Xinlikang capsules

    The experimental group was treated with Xinlikang capsules after meals, 5 capsules each time, 3 times a day for 12 weeks.

    Drug: Xinlikang capsules

  • Placebo comparator
    Mimic capsules

    The control group was treated with mimic capsules, 5 capsules each time after meals, 3 times a day for 12 weeks.

    Drug: mimic capsules

Interventions

  • DrugXinlikang capsules

    Xinlikang capsules after meals, 5 capsules each time, 3 times a day for 12 weeks

  • Drugmimic capsules

    mimic capsules, 5 capsules each time after meals, 3 times a day for 12 weeks.

06

What researchers measure

Primary outcomes

  1. The difference of FACIT Fatigue Scale score

    The scale ranges from 0 to 4, with lower scores indicating better outcomes.

    Time frame: From baseline to 12 weeks of treatment

Secondary outcomes

  1. The difference of FACIT Fatigue Scale scores

    The scale ranges from 0 to 4, with lower scores indicating better outcomes.

    Time frame: Differences in FACIT Fatigue Scale scores from baseline at the end of 2, 4, and 8 weeks of treatment.

  2. BFI

    The scale ranges from 0 to 10, with lower scores indicating better outcomes.

    Time frame: BFI differences from baseline at 2 weeks, 4 weeks, 8 weeks and 12 weeks of treatment

  3. FACT-Lym total score

    The scale ranges from 0 to 4, with lower scores indicating better outcomes.

    Time frame: FACT-Lym total score differences from baseline at 2 weeks, 4 weeks, 8 weeks and 12 weeks of treatment

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2025 (actual). Primary completion is estimated for Aug 2028, 34 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 9, 2025
First posted
Jul 24, 2025
StartActual
Sep 11, 2025
Primary completionEst.
Aug 1, 2028
CompletionEst.
Aug 1, 2030
Last update
Nov 26, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07084662
Responsible party
Qingqing Cai (MD. PhD., Sun Yat-Sen University Cancer Center) — Principal investigator
First posted
Jul 24, 2025
Start date
Sep 11, 2025
Primary completion
Aug 1, 2028 (estimated)
Completion
Aug 1, 2030 (estimated)
Last update
Nov 26, 2025

Study contacts

Qingqing Cai
Contact
caiqq@sysucc.org.cn
02087342823

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion